Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

News

ASCO 2024: DREAMM-7 Subgroup Analyses Support BVd in Resistant Myeloma
ASCO 2024: Can Idecabtagene Vicleucel Improve Outcomes in Extramedullary Multiple Myeloma?
ASCO 2024: Is Belantamab Mafodotin Making a Comeback in the DREAMM-8 Myeloma Trial?
Multiple Myeloma and Autoimmune Diseases: A Causal Relationship?
Steroid-Free Combination Therapy Under Study in Multiple Myeloma
AACR 2024: Study Reports Activity With Linvoseltamab in Resistant Myeloma
Expanded FDA Approval for Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma
Optimizing Pomalidomide-Based Therapy for Relapsed or Refractory Multiple Myeloma
Risk of Relapse: Predictions Among Patients With Ultra–High-Risk Multiple Myeloma
Biweekly Dosing Approved by the FDA for Teclistamab-cqyv in Multiple Myeloma
DREAMM-7 Supports Novel Triplet Regimen in Relapsed or Refractory Multiple Myeloma
Understanding the Clinical Impact of Progressive Smoldering Multiple Myeloma
Initial Trial Results With Novel Combination Therapy for Resistant Myeloma
Is There a Future for Microbiota-Based Treatment in Resistant Multiple Myeloma?
FDA Calls for New Boxed Warning on All CAR T-Cell Therapies
Early Results With Bispecific T-Cell Engager in High-Risk Smoldering Myeloma
NCCN Awards Grants to Study Use of BCMA-Directed Bispecific Antibody in Multiple Myeloma
Has the Risk of Infection Shifted in the Era of Novel Multiple Myeloma Agents?
New BCL2 Inhibitor Plus Dexamethasone Under Study in Relapsed or Refractory Multiple Myeloma
Can Revised FLC Reference Intervals Improve Diagnosis of Light Chain MGUS?
MonumenTAL-1 Trial: Intensity of Dosing With Talquetamab in Myeloma Under Study
Comparing Infections Rates With Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma
ASH 2023: Four-Drug vs Three-Drug Regimens Before and After ASCT in Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.